1- Avasarala J. Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms. Innov Clin Neurosci. 2017; 14(3-4): 38–40.

2- Repovic P. Management of Multiple Sclerosis Relapses. Continuum: Multiple Sclerosis and other CNS Inflammatory Diseases 2019; volume 25, No.3, p. 655-669.

3- Thompson AJ et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology 2018; volume 17, issue 2, P162-173.

4- Ziemssen et al. Secondary Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 Jan; 10(1): e200064.

5- Montalban X et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology 2018, 25: 215-237.

6- Rae-Grant A et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90:777-788. doi:10.1212/WNL.0000000000005347.

7- Yamout et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions of the MENACTRIMS guidelines. Multiple Sclerosis and Related Disorders 2020; 37: 101459.

8- Kappos L et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; volume 391, P1263-1273.

9- Montalban X et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376:209-220.

10- Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB multiple sclerosis study group. Neurology 43 (4), 655–661.

11- Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis, 1998. PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group. Lancet 352 (9139), 1498–1504.

12- Johnson et al., 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group. Neurology 45 (7), 1268–1276.

13- Kappos L et al., 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362 (5), 387–401.

14- Cohen JA et al., 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362 (5), 402–415.

15- Confavreux C et al., 2014. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 13 (3), 247–256.

16- Viglietta V et al., 2015. Efficacy of delayed-release dimethyl fumarate in relapsing remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann. Clin. Transl. Neurol. 2 (2), 103–118.

17-  Polman CH et al., 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (9), 899–910.

18- Hauser SL et al., 2017. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376 (3), 221–234.

19- Giovannoni G., et al., 2010. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362 (5), 416–426.

20- Kappos L et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol.  2021 May 1; 78(5):558-567.

21- Rahmanzadeh R. et al., 2018. B cells in multiple sclerosis therapy-A comprehensive review. Acta Neurol. Scand. 137 (6), 544–556.

22- Spelman T et al., 2018. Comparative effectiveness of rituximab relative to IFN-beta or glatiramer acetate in relapsing-remitting MS from the SWEDISH MS registry. Mult. Scler. 24 (8), 1087–1095.

23- Salzer J et al., 2016. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87 (20), 2074–2081.